コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tients with localized kidney cancer, such as nephron-sparing and minimally invasive techniques are si
6 D kidneys based on nephron mass matching and nephron sparing measures may provide optimal utilization
7 y is now performed as a standard therapeutic nephron-sparing option in patients who are poor candidat
8 ned patients who might benefit from elective nephron-sparing procedures without increasing the risk o
9 y reviewed our institutional experience with nephron sparing surgery (NSS) in patients with synchrono
10 pointing to the long-term health benefits of nephron sparing surgery over radical nephrectomy and its
11 l targeted molecular therapies (TMTs) before nephron-sparing surgery (NSS) in patients with renal cel
15 r time (from 69.0% to 42.5%), and the use of nephron-sparing surgery (partial nephrectomy and ablatio
17 such as gene expression profiling, PET, and nephron-sparing surgery are being incorporated into cont
21 the role of ultrasound screening followed by nephron-sparing surgery for some patients may be appropr
23 o further spare renal parenchyma and perform nephron-sparing surgery in anatomically difficult scenar
30 g surgery, multiple absolute indications for nephron-sparing surgery still exist, including the class
31 extending the benefits of minimally invasive nephron-sparing surgery to a wider audience of patients
32 tients who received surgical treatment, only nephron-sparing surgery was associated with a benefit in
33 ques such as gene expression profiling, PET, nephron-sparing surgery, and stem cell transplantation a
34 areness has increased regarding the value of nephron-sparing surgery, even in the presence of a norma
36 the controversy surrounding the benefits of nephron-sparing surgery, multiple absolute indications f
47 tients with a small renal tumor is a form of nephron-sparing tumor excision or ablation, as this appr